Inhibitor Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Inhibitor Therapeutics generated cash of -$2,700,312, which is less than the previous year. Cash used in financing activities reached the amount of -$411,000 last year. Net change in cash is therefore -$3,111,312.
Cash Flow
| 2014 | -1.30M | 0 | 1.66M |
|---|---|---|---|
| 2015 | -2.26M | 0 | 2.5M |
| 2016 | -3.75M | 0 | 10.04M |
| 2017 | -2.91M | 0 | -3.62M |
| 2018 | -3.70M | 0 | 4.47M |
| 2019 | -2.70M | 0 | 2.40M |
| 2020 | -825.35K | 0 | 96.6K |
| 2021 | -220.43K | 0 | 176K |
| 2022 | 11.74M | 0 | 180K |
| 2023 | -2.70M | 0 | -411K |
INTI Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 11.95M | 30.62K | 75.05K | 803.81K | 1.10M | 344.11K | 6.88M | 601.44K | 365.16K | 217 |
Operating activities | ||||||||||
Net income | -3.02M | 12.10M | -298.63K | -1.05M | -2.73M | -4.55M | -5.10M | -7.00M | -3.94M | -3.97M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 13.78K | 0 | 37.99K | 228.86K | 269.92K | 0 | 1.86M | 3.56M | 1.72M | 753.58K |
| Deferred income tax benefit | 13.78K | 0 | 37.99K | 228.86K | 269.92K | 0 | 1.86M | 3.56M | 1.72M | 753.58K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 397.38K | 137.82K | 53.26K | -35.73K | -270.42K | -785 | 293.35K | -153.74K | 150.98K | 61.32K |
Cash generated by operating activities | -2.70M | 11.74M | -220.43K | -825.35K | -2.70M | -3.70M | -2.91M | -3.75M | -2.26M | -1.30M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 200K | 200.54K | 99.94K | 3.96M | 49.5K | 5.50M | 2.5M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | -99.17K | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -176K | -96.6K | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -411K | 180K | -176K | -96.6K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | -411K | 180K | 176K | 96.6K | 2.40M | 4.47M | -3.62M | 10.04M | 2.5M | 1.66M |
Net Change In Cash | -3.11M | 11.92M | -44.43K | -728.75K | -304.89K | 764.6K | -6.54M | 6.28M | 236.28K | 364.94K |
Cash at end of period | 8.83M | 11.95M | 30.62K | 75.05K | 803.81K | 1.10M | 344.11K | 6.88M | 601.44K | 365.16K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |